Merck & Co. is a diversified global biopharmaceutical company whose Pharmaceutical segment supplies the majority of revenue, complemented by Animal Health. Its principal competitive advantages are extensive clinical evidence, broad regulatory labels, physician switching costs, manufacturing scale and patent protection. The United States generated $36.51 billion, or 56.16% of FY2025 sales, while total FY2025 revenue reached $65.01 billion. **The central investment issue is the 2028–2029 Keytruda patent cliff:** Keytruda contributes approximately 55% of pharmaceutical sales, making successful conversion to Keytruda Qlex and replacement-product launches critical. The underlying business remains resilient: Q1 2026 revenue was $16.29 billion, 5% nominal growth, and exceeded consensus by 2.52%, while non-GAAP EPS loss of $1.28 beat expectations despite a $9.0 billion Cidara-related charge. Winrevair reached $525 million and Ohtuvayre $131 million in Q1 sales, but Gardasil declined 19% and Januvia/Janumet declined 28%. Merck trades at 13.52x forward P/E versus a 19.42x healthcare average. Near-term catalysts include Keytruda and Welireg regulatory decisions, pipeline readouts, Terns integration and Chinese Gardasil inventory stabilization. The report views the shares as an undervalued, income-oriented transitional opportunity rather than a low-risk compounder.

Merck & Co Inc (MRK) Investment Analysis

1. Executive Summary

Merck & Co Inc operates as a premier global biopharmaceutical entity dedicated to discovering, developing, and commercializing prescription medicines, biological therapies, vaccines, and animal health products.[1] The business structure is split into two primary operational segments: the Pharmaceutical segment, which represents the core engine of corporate revenue, and the Animal Health segment.[2] Under the Pharmaceutical umbrella, the company commercializes high-value therapeutics targeting oncology, immunology, vaccines, infectious diseases, and cardiovascular-respiratory conditions.[2, 3] The Animal Health segment provides veterinary pharmaceuticals, parasiticide programs, and digitally integrated identification and traceability systems for livestock and companion animals.[2, 4]

Revenue generation is highly diversified across several key global geographies, with the United States remaining the largest single market, bringing in $36.51 billion, or 56.16%, of total sales in fiscal year 2025.[5] Other key geographical regions include Europe, Middle East, and Africa (EMEA) at $14.58 billion (22.43%), Latin America at $3.41 billion (5.25%), the Asia-Pacific region excluding Japan and China at $2.98 billion (4.59%), Japan at $2.71 billion (4.17%), and China at $1.94 billion (2.98%).[5] Additional international revenue streams contribute another $2.88 billion (4.43%) to the consolidated corporate top line.[5]

The primary customer base consists of drug wholesalers, pharmaceutical distributors, hospitals, government procurement agencies, physician networks, and veterinary clinics.[2, 4, 6] Customers consistently select Merck over therapeutic alternatives due to the company's robust clinical data packages, superior therapeutic efficacy, established safety records, and extensive patent portfolios that severely restrict the availability of low-cost generic substitutes.[2, 6, 7]

2. Business Drivers & Strategic Overview

The commercial success and long-term viability of Merck are dictated by its leading oncology franchise, its vaccine portfolio, and its aggressive strategic business development deals intended to mitigate future patent expirations.[2, 8, 9]

Product Portfolio Detail

In oncology, the flagship pembrolizumab franchise comprises Keytruda and the subcutaneous formulation Keytruda Qlex.[4, 6] Keytruda is approved for 44 distinct FDA indications across 19 tumor types, along with two tumor-agnostic approvals, representing approximately 55% of total pharmaceutical sales.[7] Keytruda Qlex, which generated $128 million in sales during the first quarter of 2026, represents a critical subcutaneous delivery platform that was awarded a permanent billing J-code on April 1, 2026.[10, 11] This J-code streamlines healthcare provider reimbursement in the United States, driving clinical adoption of the subcutaneous format.[6, 11] Welireg (belzutifan) also serves as a key oncology driver for renal cell carcinoma, registering $199 million in first-quarter 2026 sales (a 43% year-over-year increase).[4, 11]

In vaccines, the leading asset is Gardasil/Gardasil 9, which protects against HPV-related cancers.[2, 12] Gardasil generated $5.23 billion in full-year 2025 revenue, down from $8.58 billion in fiscal year 2024 due to challenging economic conditions and inventory clearing in China.[2] Winrevair (sotatercept) represents a major cardiometabolic and respiratory driver for pulmonary arterial hypertension (PAH), scaling rapidly to reach $525 million in first-quarter 2026 sales.[4, 11] In addition, Ohtuvayre (ensifentrine), acquired via Verona Pharma in late 2025, serves as a key maintenance therapy for chronic obstructive pulmonary disease (COPD), bringing in $131 million in the first quarter of 2026.[11, 13, 14]

Economic Moat Analysis

Merck possesses a wide economic moat supported by regulatory barriers, high physician switching costs, massive manufacturing scale, and global distribution dominance.[2, 6, 7] The oncology business benefits from high switching costs, as physicians are reluctant to alter established treatment regimens for active cancer patients.[7] However, Keytruda’s core U.S. patent is expected to expire around 2028–2029, exposing the franchise to biosimilar competition.[7, 8] To defend this high-margin revenue stream, Merck is shifting patients to Keytruda Qlex, which utilizes advanced formulation patents that extend market exclusivity post-2028.[2, 6]

Total Addressable Market (TAM) Analysis

The total addressable market across oncology, vaccines, respiratory, and hematology is expanding.[9, 15] Management expects its pipeline of over 20 new growth drivers to yield more than $70 billion in potential annual non-risk-adjusted revenue by the mid-2030s.[10, 15] This is double the $35 billion peak annual sales Keytruda is projected to generate before its LOE.[8] To capture this market, Merck has deployed significant capital through strategic acquisitions:

• Verona Pharma ($10.0 Billion): Completed in October 2025, securing Ohtuvayre for COPD maintenance, which expands Merck's presence in respiratory medicine.[13, 14, 16]
• Cidara Therapeutics ($9.2 Billion): Completed on January 7, 2026, acquiring CD388, a strain-agnostic, long-acting drug-Fc conjugate (DFC) designed to provide season-long influenza prevention.[16, 17, 18] CD388 bypasses active immune responses, targeting a substantial market opportunity of over $5 billion by the next decade.[8, 18]
• Terns Pharmaceuticals ($6.7 Billion): Completed on May 5, 2026, adding TERN-701, an oral, allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI) currently in Phase 1/2 development for chronic myeloid leukemia (CML).[19, 20] TERN-701 has Breakthrough Therapy designation and holds significant commercial potential in hematology.[20, 21]

Competitive Landscape

The competitive environment is intensifying across Merck's primary franchises:

• Oncology Bispecifics: Keytruda faces emerging threats from dual PD-1/VEGF bispecific antibodies.[7, 22] Notably, ivonescimab (developed by Akeso and licensed to Summit Therapeutics) demonstrated head-to-head clinical superiority over pembrolizumab in non-small cell lung cancer trials in China (HARMONi-2), cutting the risk of disease progression or death by 48%.[23, 24] While global approvals require robust overall survival datasets in Western cohorts, bispecific constructs from Summit, BioNTech, and Bristol Myers Squibb represent a credible threat to Keytruda’s standard of care.[22, 24]
• PAH Competition: Winrevair faces a potential threat from United Therapeutics’ ralinepag, a once-daily oral prostacyclin receptor agonist.[25, 26] In its Phase 3 ADVANCE OUTCOMES study, ralinepag cut the risk of clinical worsening by 55% versus placebo, establishing a competitive alternative to Winrevair and J&J's twice-daily Uptravi.[25, 26]

3. Financial Performance & Valuation

Analyzing the latest financial materials reveals how Merck's underlying business operations are performing relative to near-term generic headwinds and M&A transaction charges.

Latest Quarterly Performance (Q1 2026)

Merck announced its first-quarter 2026 financial results on April 30, 2026.[4] The company delivered nominal sales growth of 5% and ex-exchange growth of 3% compared to the prior-year period.[4]

• Revenue Performance: Total worldwide revenue reached $16.29 billion, surpassing the consensus analyst expectation of $15.89 billion by 2.52%.[4, 27]
• Earnings Per Share (EPS): Merck reported a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28.[4] This non-GAAP result beat analyst expectations of a non-GAAP loss of $1.48 by 13.51%, representing a positive surprise.[27]
• One-Time Charge: The reported net loss was driven by a $9.0 billion one-time, non-tax-deductible charge (or $3.62 per share) associated with the completion of the Cidara Therapeutics asset acquisition on January 7, 2026.[4, 11, 17] Excluding this charge, non-GAAP operating expenses grew by 2% year-over-year.[11]
• Gross Margin: Non-GAAP gross margin was 81.9%, down slightly from 82.2% in Q1 2025, driven by product mix and the immediate impact of the Cidara transaction.[11] GAAP gross margin declined to 74.2% from 78.0% due to acquisition-related costs.[4]

Segment and Product Line Performance

The Pharmaceutical segment generated $14.35 billion in Q1 2026, representing 5% nominal and 2% ex-exchange growth.[4]

• Oncology: Keytruda family sales rose 12% nominal (8% ex-exchange) to $8.03 billion, driven by uptake in earlier-stage breast and cervical cancers, alongside combination use with Padcev in first-line urothelial cancer.[4, 11] U.S. sales benefited by $250 million from the timing of wholesaler purchases.[11]
• Vaccines: Gardasil sales declined 19% nominal (22% ex-exchange) to $1.07 billion due to lower public-sector purchasing patterns in the United States and continued demand contraction in China and Japan.[4]
• Cardiometabolic & Respiratory: Winrevair grew to $525 million, reflecting strong ongoing global uptake.[4, 11] Conversely, Ohtuvayre sales of $131 million were impacted by Medicare deductible resets and CMS reimbursement adjustments, though prescription trends began recovering in late March.[11, 13]
• Diabetes: Januvia/Janumet sales declined 28% nominal (29% ex-exchange) to $574 million, driven by lower net pricing and generic competition in the United States and international markets.[4]

Guidance and Outlook Adjustments

During the April 30, 2026 earnings announcement, Merck narrowed and raised its full-year 2026 financial guidance:

• Consolidated Sales: The expected revenue range was adjusted to between $65.8 billion and $67.0 billion (representing 1% to 3% growth), up from the prior range of $65.5 billion to $67.0 billion.[3, 4]
• Non-GAAP EPS: The non-GAAP EPS guidance was raised to between $5.04 and $5.16, up from the prior range of $5.00 to $5.15.[3, 4] This updated guidance includes a positive $0.10 foreign exchange benefit and incorporates the $3.65 per share Cidara transaction charge.[3, 6]
• Terns Exclusion: This guidance excludes the proposed Terns Pharmaceuticals acquisition, which completed on May 5, 2026.[6, 20] The completed Terns transaction is expected to trigger a second-quarter 2026 R&D asset acquisition charge of approximately $5.8 billion, or $2.35 per share, along with a $0.12 per share negative impact on 2026 EPS to support clinical development costs.[20]

Management Commentary and Strategic Partnerships

During the first-quarter earnings call, management focused on portfolio transformation and clinical execution.[6, 15] CEO Rob Davis highlighted the progress of over 20 new blockbuster launches, noting that strategic deals are diversifying the company's commercial drivers.[6, 15] In research and development, MRL President Dean Li discussed the company's clinical analysis of the CML candidate TERN-701.[6, 28] He emphasized the importance of translating early trial data into conservative regulatory standards, maintaining Merck’s disciplined approach to clinical development.[6, 28]

Additionally, Merck is utilizing partnerships to integrate artificial intelligence (AI) across its business.[6, 11] The company announced a multi-year partnership with Google Cloud to scale advanced AI, data, and agentic capabilities.[6, 11] This complements its expanded collaboration with Tempus AI to advance its precision oncology strategy, alongside an agreement with the Mayo Clinic to leverage clinical and genomic data sets.[6, 11]

Valuation Analysis and Historical Context

To connect Merck's valuation to its core business, investors must analyze its historical growth trajectory and intermediate-term headwinds. Between 2020 and 2025, Merck's annual revenue grew from $41.52 billion to $65.01 billion.[29] This represents a 5-year historical Compound Annual Growth Rate (CAGR) of 9.38%, calculated using the following formula:

$\text{CAGR} = \left(\frac{\$65.01\text{B}}{\$41.52\text{B}}\right)^{\frac{1}{5}} - 1 \approx 9.38\%$

Despite this solid historical growth, Merck trades at a forward P/E ratio of 13.52x, below the healthcare sector's average of 19.42x.[30, 31] This discount reflects the market's pricing of the "Keytruda patent cliff risk".[7, 8] The company also faces near-term generic headwinds, with competition in 2026 for Januvia, Bridion, and Dificid expected to impact sales by approximately $2.5 billion.[7] Thus, Merck's future valuation depends on the execution of its subcutaneous transition (Keytruda Qlex) and the commercialization of its newly acquired candidates (Winrevair, Ohtuvayre, CD388, and TERN-701) to replace this eroding revenue base.[2, 6, 9]

Segment and Geographical Financial Tables

To present Merck's financial performance effectively, Table 1 details the geographical revenue distribution for full-year 2025, while Table 2 outlines the product and alliance revenue performance for the first quarter of 2026.

Geographical Region	FY2025 Revenue (USD)	Percent of Total Revenue	Year-over-Year Change (%)
United States	$36.51 Billion [5]	56.16% [5]	+13.11% [5]
EMEA	$14.58 Billion [5]	22.43% [5]	+3.84% [5]
Latin America	$3.41 Billion [5]	5.25% [5]	-1.42% [5]
Asia Pacific (excl. Japan/China)	$2.98 Billion [5]	4.59% [5]	-2.45% [5]
Japan	$2.71 Billion [5]	4.17% [5]	-17.35% [5]
China	$1.94 Billion [5]	2.98% [5]	-64.71% [5]
Other International	$2.88 Billion [5]	4.43% [5]	+12.47% [5]
Total Sales	$65.01 Billion [5]	100.00%	+1.31% [5]

Table 1: Geographical Revenue Distribution (FY2025)

Product / Alliance Category	Q1 2026 Sales (USD)	Q1 2025 Sales (USD)	Nominal Change (%)	ex-FX Change (%)
Keytruda Family	$8.03 Billion [4]	$7.21 Billion [4]	+12.0% [4]	+8.0% [4]
Gardasil/Gardasil 9	$1.07 Billion [4]	$1.33 Billion [4]	-19.0% [4]	-22.0% [4]
Januvia/Janumet	$574 Million [4]	$796 Million [4]	-28.0% [4]	-29.0% [4]
Winrevair	$525 Million [4]	$280 Million [13]	+88.0% [4]	+87.0% [4]
Proquad / M-M-R II / Varivax	$538 Million [4]	$539 Million [4]	0.0% [4]	-2.0% [4]
Bravecto (Animal Health)	$379 Million [4]	$327 Million [4]	+16.0% [4]	+9.0% [4]
Lynparza Alliance Revenue	$341 Million [4]	$312 Million [4]	+9.0% [4]	+6.0% [4]
Lenvima Alliance Revenue	$256 Million [13]	$255 Million [13]	0.0% [13]	-2.0% [13]
Welireg	$199 Million [4]	$137 Million [13]	+45.0% [4]	+43.0% [4]
Ohtuvayre	$131 Million [13]	—	—	—

Table 2: Product and Alliance Revenue (Q1 2026)

4. Risk Assessment & Macroeconomic Considerations

Merck's business model is exposed to structural, competitive, regulatory, and macroeconomic vulnerabilities.

Risk Profiles and Execution Concerns

• Company-Specific Execution Risks: Merck's long-term growth is heavily dependent on M&A.[7, 21] The integration of Verona Pharma, Cidara Therapeutics, and Terns Pharmaceuticals represents over $25 billion in combined capital deployment.[16, 32] The risk is that these candidates experience clinical trial failures or fail to achieve blockbuster status.[11] Early Warning Sign: Clinical trial delays, CRLs from the FDA, or a downward revision of the non-risk-adjusted $70 billion mid-2030s revenue guidance.[15] Worst-Case Impact: Heavy asset write-downs, a lower return on invested capital, and an unhedged patent cliff.[8, 33]
• Competitive Risks: Dual PD-1/VEGF bispecifics (e.g., ivonescimab) could compete with Keytruda's oncology position.[7, 22] In PAH, United Therapeutics' ralinepag could limit Winrevair's peak market share.[25, 26] Early Warning Sign: A decline in new patient market share for Keytruda in first-line non-small cell lung cancer or slow prescription growth for Winrevair.[7, 11] Worst-Case Impact: Margin compression in oncology and a failure of the subcutaneous Keytruda Qlex transition to retain patient volume.[6, 7]
• Customer Concentration and Demand Risks: The Gardasil franchise is dependent on discretionary, out-of-pocket spending in China distributed via Chongqing Zhifei.[34, 35, 36] The 64.71% collapse in China sales in 2025 highlights this concentration risk.[5] Early Warning Sign: Failure of Zhifei to clear excess inventory or further restructuring of the distribution deal.[34, 36] Worst-Case Impact: Permanent impairment of Gardasil's peak growth trajectory, requiring a write-down of long-term cash flow assumptions.[7, 36]
• Regulatory and Legal Risks: The Inflation Reduction Act (IRA) in the United States enables government price negotiation, which, alongside the most-favored-nation agreement, imposes pricing pressure on Keytruda sales post-2029.[2] Early Warning Sign: Accelerated timelines for Medicare drug price negotiations. Worst-Case Impact: Structural margin compression across the U.S. portfolio, curtailing cash available for R&D reinvestment.[2]
• Balance Sheet and Capital Allocation Risks: Intense business development spending has driven near-term pre-tax losses and increased debt.[4, 20] Merck's payout ratio is currently elevated, which limits cash flow reinvestment if revenues decline.[37] Early Warning Sign: Rating agency downgrades or a reduction in annual share buyback targets.[33] Worst-Case Impact: A credit rating downgrade that increases capital costs and threatens dividend sustainability.[33, 37]
• Industry Structure Risks: The biopharmaceutical sector requires heavy R&D investment ($15.8 billion for Merck in 2025) and faces long clinical timelines.[1, 38] Early Warning Sign: Rising clinical trial costs. Worst-Case Impact: A structural decline in biopharmaceutical industry R&D productivity.
• Macroeconomic Sensitivities: Merck is exposed to foreign exchange fluctuations, which impact net sales growth.[4, 6] Geopolitically, trade disputes between the United States and China have resulted in retaliatory tariffs.[34] Additionally, economic deceleration in China directly impacts consumer discretionary spending on non-reimbursed healthcare, including Gardasil.[34, 35] Early Warning Sign: Continued Chinese housing market weakness and lower consumer confidence.[12] Worst-Case Impact: Structural impairment of the emerging markets expansion strategy.

Risk Categorization Matrix

To distinguish between varying degrees of risk, the following framework outlines the conditions that could impact the investment thesis:

• What Could Go Wrong: Clinical trial failures for newly acquired assets (such as TERN-701 or CD388), persistent economic deceleration in China impacting Gardasil vaccine sales, or faster-than-expected generic erosion of Januvia and Bridion.[7, 19, 35]
• Early Warning Signs: A decline in newly initiated prescriptions for Winrevair, failure of Chongqing Zhifei to clear excess vaccine inventory, or clinical trial delays for the subcutaneous formulation of Keytruda.[7, 11, 34]
• Long-Term Thesis Damage: Head-to-head clinical trial wins by competitive bispecific antibodies (such as ivonescimab) in Western oncology markets, leading to rapid market-share erosion for Keytruda, combined with a failure of Keytruda Qlex to retain clinical volume post-2028.[6, 7, 22]

5. 5-Year Scenario Analysis

The 5-year scenario analysis models Merck's financial performance and share price trajectory through Year 5 (FY2030), utilizing FY2025 (Revenue: $65.01 billion, Shares Outstanding: 2.47 billion) as the baseline year.[29, 39]

Financial and Operational Assumptions

These scenarios focus on normalized operational performance by excluding non-recurring asset acquisition charges (such as the $9.0 billion Cidara and $5.8 billion Terns write-downs) to evaluate underlying cash flow and earnings power.[4, 20]

• Base Case (60% Probability): Merck achieves moderate top-line expansion, registering a 3.0% revenue CAGR. Keytruda sales slow ahead of the LOE but are insulated by a successful transition of 60% of patients to Keytruda Qlex.[6, 7] Winrevair, Ohtuvayre, and Capvaxive continue steady commercial uptake, offsetting the $2.5 billion Januvia/Bridion generic headwind and weak Chinese Gardasil demand.[7, 11] Normalized non-GAAP net margin stabilizes at 30.0%.[33] Annual share buybacks of approximately $3.0 billion, offset by employee equity grants, reduce the outstanding share count by 1.0% annually, down to 2.35 billion shares.[33, 39]
• High Case (25% Probability): Revenue grows at a 5.5% CAGR. The subcutaneous Keytruda Qlex transition is highly successful, capturing 75%+ of the oncology volume.[6] Gardasil demand in China rebounds strongly under the demand-based distribution model, and newly approved male indications drive volume.[12, 36] Winrevair successfully blocks competitive threats from ralinepag, while CD388 (influenza) and TERN-701 (CML) launch as blockbusters.[16, 21, 26] Operating leverage expands the normalized net margin to 33.0%.[33] Aggressive cash generation supports expanded share repurchases, reducing the share count by 1.4% annually to 2.30 billion shares.
• Low Case (15% Probability): Revenue registers flat growth at a 0.5% CAGR. Keytruda faces severe competitive erosion from bispecific antibodies and biosimilars, while the Keytruda Qlex transition fails to gain meaningful traction.[7, 22] Winrevair loses market share to United Therapeutics' once-daily ralinepag.[26] Gardasil demand in China remains structurally depressed due to local low-cost vaccine competition and weak discretionary consumer spending.[35, 36] Pricing pressure from the IRA and MFN agreements compresses the net margin to 25.0%.[2] Reduced free cash flow limits buybacks, keeping the share count relatively flat at 2.45 billion shares.

Valuation and Exit Multiple Assumptions

The exit multiples applied in Year 5 (FY2030) are adjusted to reflect the visibility of Merck's pipeline at that stage:

• Base Case: A forward P/E multiple of 14.5x is applied. This represents a minor expansion from current forward levels, reflecting reduced uncertainty as the company successfully navigates the peak of the Keytruda patent cliff.[7, 30]
• High Case: A P/E multiple of 16.5x is applied, justified by high-growth pipeline execution and strong commercial launches of CD388 and TERN-701, which re-establish Merck as a multi-franchise growth leader.[16, 21]
• Low Case: A P/E multiple of 11.5x is applied, reflecting a permanently lower growth profile, severe oncology erosion, and pipeline underperformance.[7, 33]

Financial Bridge and Share Price Outcomes

The financial bridge models how these operating assumptions translate into the Year 5 share price and total return, assuming cumulative dividend payouts of $17.00 in the Base Case ($3.40 annually), $17.50 in the High Case, and $16.00 in the Low Case.[37, 40]

• Base Case Bridge:
  • Year 5 Revenue: $\$65.01\text{B} \times (1.03)^5 = \$75.36\text{B}$
  • Year 5 Normalized Net Income: $\$75.36\text{B} \times 30.0\% = \$22.61\text{B}$
  • Year 5 EPS: $\$22.61\text{B} / 2.35\text{B shares} = \$9.62$
  • Year 5 Share Price: $\$9.62 \times 14.5 = \$139.49$
  • 5-Year Total Return: $\frac{\$139.49 + \$17.00}{\$123.54} - 1 = 26.67\%$ (4.84% annualized)
• High Case Bridge:
  • Year 5 Revenue: $\$65.01\text{B} \times (1.055)^5 = \$85.03\text{B}$
  • Year 5 Normalized Net Income: $\$85.03\text{B} \times 33.0\% = \$28.06\text{B}$
  • Year 5 EPS: $\$28.06\text{B} / 2.30\text{B shares} = \$12.20$
  • Year 5 Share Price: $\$12.20 \times 16.5 = \$201.30$
  • 5-Year Total Return: $\frac{\$201.30 + \$17.50}{\$123.54} - 1 = 77.11\%$ (12.11% annualized)
• Low Case Bridge:
  • Year 5 Revenue: $\$65.01\text{B} \times (1.005)^5 = \$66.65\text{B}$
  • Year 5 Normalized Net Income: $\$66.65\text{B} \times 25.0\% = \$16.66\text{B}$
  • Year 5 EPS: $\$16.66\text{B} / 2.45\text{B shares} = \$6.80$
  • Year 5 Share Price: $\$6.80 \times 11.5 = \$78.20$
  • 5-Year Total Return: $\frac{\$78.20 + \$16.00}{\$123.54} - 1 = -23.75\%$ (-5.27% annualized)

Probability-Weighted Target Price

Applying subjective probability weights of 60% to the Base Case, 25% to the High Case, and 15% to the Low Case yields a probability-weighted Year 5 target share price of $145.75:

$\text{Weighted Price} = (\$139.49 \times 0.60) + (\$201.30 \times 0.25) + (\$78.20 \times 0.15) = \$83.69 + \$50.33 + \$11.73 = \$145.75$

This target price of $145.75, when combined with weighted cumulative dividends of $16.98, implies a 5-year total return of 31.72% (or a 5.66% annualized return) relative to the current share price of $123.54.[41]

Trajectory and Scenario Comparison Tables

To track the projected share price development under each scenario, Table 3 models the estimated trajectory from Year 1 to Year 5, while Table 4 provides the consolidated scenario comparison.

Scenario	Year 0	Year 1	Year 2	Year 3	Year 4	Year 5
High Case	$123.54 [41]	$135.50	$149.30	$164.80	$182.10	$201.30
Base Case	$123.54 [41]	$126.50	$129.50	$132.70	$136.00	$139.49
Low Case	$123.54 [41]	$112.50	$102.50	$93.50	$85.50	$78.20

Table 3: Implied 5-Year Share Price Trajectory (USD)

Scenario	Revenue in Year 5	Margin Assumption	Exit Multiple	Current Price	Implied future Price	5-Year Return	Annualized Return	Probability
High Case	$85.03 Billion	33.0% Net	16.5x P/E	$123.54 [41]	$201.30	77.11%	12.11%	25%
Base Case	$75.36 Billion	30.0% Net	14.5x P/E	$123.54 [41]	$139.49	26.67%	4.84%	60%
Low Case	$66.65 Billion	25.0% Net	11.5x P/E	$123.54 [41]	$78.20	-23.75%	-5.27%	15%
Weighted	$76.15 Billion	29.7% Net	14.3x P/E	$123.54 [41]	$145.75	31.72%	5.66%	100%

Table 4: 5-Year Valuation Scenario Matrix

BALANCED TRANSITIONAL VALUE

6. Qualitative Scorecard

To evaluate the non-financial and strategic elements of the investment thesis, Merck is rated on a scale of 1 to 10 across ten core pillars.

• Management Alignment (8/10): CEO Robert M. Davis maintains strong alignment with shareholders, directly holding 450,350.757 shares of common stock, valued at over $55 million.[41, 42] Executive compensation is heavily performance-based, with 74% of total FY2025 pay delivered via equity.[43] In FY2025, the Company Scorecard funded annual cash incentives at 94% of target, and the performance share unit program also paid out at 94% of target.[38] Shareholder support for executive pay remains high, with the say-on-pay proposal receiving 91% approval in 2025.[38]
• Revenue Quality (7/10): Operational revenue is backed by high-margin clinical therapies, resulting in structurally high non-GAAP gross margins of approximately 82%.[4] However, revenue quality is impacted by concentration, with the Keytruda franchise representing over 55% of total pharmaceutical sales.[7] Additionally, the high volatility of Gardasil sales in China exposes the vaccine portfolio to distributor channel risks.[34, 36]
• Market Position (8/10): Merck occupies a leading global position in immuno-oncology, pneumococcal vaccines, and Animal Health veterinary medicine.[2, 4] While it faces rising market-share pressure from emerging bispecific antibodies and domestic Chinese vaccine alternatives, its established provider networks and broad label indications allow it to defend its market footprint.[7, 22, 35]
• Growth Outlook (7/10): The long-term growth outlook is supported by a potential $70 billion peak commercial opportunity by the mid-2030s.[15] However, the near-term outlook (2026–2028) faces headwind pressures, including $2.5 billion in generic erosion from Januvia, Bridion, and Dificid in 2026, alongside flat overall growth expected for Gardasil.[7]
• Financial Health (9/10): Merck boasts strong capital generation, delivering over $14 billion in annual free cash flow.[30] This provides excellent liquidity to support substantial dividend payouts and absorb large cash transactions without compromising balance sheet stability.[20, 33]
• Business Viability (7/10): The core business model is highly durable, but the upcoming 2028–2029 Keytruda LOE represents a critical structural choke point.[7, 8] If subcutaneous conversion and pipeline assets fail to scale, the business will face a severe revenue and margin contraction post-2028.[2, 7]
• Capital Allocation (8/10): Capital allocation is characterized by disciplined, science-led M&A (Verona, Cidara, Terns) that targets de-risked, late-stage assets.[15, 20] While these acquisitions cause near-term GAAP earnings volatility due to heavy asset acquisition charges, they are strategically aligned to replenish the pipeline ahead of the Keytruda patent cliff.[4, 21]
• Analyst Sentiment (9/10): Sentiment remains overwhelmingly positive, with 19 buy ratings, 9 hold ratings, and only 1 sell rating.[30] Covering institutions view recent pipeline developments and the restructured Zhifei agreement as positive steps.[31, 36]
• Profitability (8/10): Merck delivers strong non-GAAP operating profitability, supported by premium pricing and manufacturing efficiencies.[4, 6] However, GAAP net profit margins are frequently compressed by multi-billion dollar upfront R&D transaction charges from intense dealmaking activity.[4, 20]
• Track Record (8/10): The company has a solid history of shareholder value creation, maintaining a dividend growth streak of 15 consecutive years with a robust forward dividend yield of over 2.6%.[27, 30, 31]

Blended Score Summary

Averaging the scores across all ten pillars yields a blended rating of 7.9 out of 10. This score reflects a fundamentally strong, cash-generative business that is navigating a critical pipeline and clinical transition.

TRANSITIONAL CORE POWER

7. Conclusion & Investment Thesis

Merck is a high-conviction transitional case in the global biopharmaceutical sector. The investment thesis hinges on the company's ability to successfully execute its clinical pipeline transition to offset the upcoming patent cliff for Keytruda, its multi-billion dollar oncology driver, starting in 2028.[7, 8]

The core strength of the business is represented by its highly cash-generative base, led by Keytruda's ongoing expansion in earlier-stage cancers, the rapid commercial scaling of Winrevair in PAH, and the integration of newly launched Ohtuvayre in COPD.[4, 11] While the Gardasil vaccine franchise faces structural demand headwinds in China, the recent restructuring of the Zhifei distribution agreement to a rolling, demand-based model through 2028 represents a necessary step to stabilize channel inventory and reduce near-term margin volatility.[36]

To replace the revenue risk associated with Keytruda's patent cliff and near-term generic pressure on Januvia and Bridion, Merck is deploying its robust cash flow toward disciplined late-stage acquisitions.[7, 21] The successful buyouts of Cidara Therapeutics (bringing in the Phase 3 influenza antiviral CD388) and Terns Pharmaceuticals (acquiring the Breakthrough-designated CML asset TERN-701) expand and diversify the clinical pipeline.[16, 19, 20] These acquisitions contribute to a projected peak commercial opportunity of over $70 billion by the mid-2030s.[15]

Near-term catalysts to monitor include upcoming FDA regulatory decisions on Keytruda in muscle-invasive bladder cancer, Welireg label updates, and phase 3 data readouts for novel candidates over the next 12 to 18 months.[6, 9] Risk factors include competitive pressure from dual PD-1/VEGF bispecifics (ivonescimab) and United Therapeutics' ralinepag in PAH.[22, 25] However, at a forward P/E of 13.52x, the market appears to be discounting Merck's pipeline execution capabilities, offering a solid entry point for long-term, income-focused portfolios.[30, 31]

UNDERVALUED CLINICAL TRANSITION

8. Technical Analysis, Price Action & Short-Term Outlook

Merck's current share price of $123.54 sits comfortably above its simple 200-day moving average of $107.46, indicating a strong medium-term bullish trend and positive investor accumulation.[41, 44] The stock has established a rising trend channel and recently broke through resistance levels to achieve a new 52-week high of $129.69.[45, 46] In the short term, the Relative Strength Index of 62.16 indicates that while momentum remains firmly upward, the stock is gradually approaching overbought territory.[30] Investors should anticipate brief consolidation near these peak levels ahead of the next quarterly earnings release on August 4, 2026, where progress on the Terns integration and Gardasil inventory stabilization in China will serve as key directional catalysts.[20, 36, 47]

BULLISH CHANNEL CONSOLIDATION

---

1. Company fact sheet - Merck.com, https://www.merck.com/media/company-fact-sheet/
2. Merck 2025 sales 65,011 million on oncology strength | MRK Annual Report (10-K), https://www.stocktitan.net/sec-filings/MRK/10-k-merck-co-inc-files-annual-report-84b73c52470e.html
3. Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline, https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/
4. Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones, https://www.merck.com/news/merck-co-inc-rahway-n-j-usa-announces-first-quarter-2026-financial-results-highlights-significant-regulatory-approvals-and-clinical-milestones/
5. Merck & Co.'s Revenue by Region - Bullfincher, https://bullfincher.io/companies/merck-co/revenue-by-geography
6. Merck (MRK) Q1 2026 Earnings Call Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/04/30/merck-mrk-q1-2026-earnings-call-transcript/
7. MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels? - TradingView, https://www.tradingview.com/news/zacks:5033d2e89094b:0-mrk-surpasses-50-200-day-smas-buy-hold-or-sell-at-current-levels/
8. Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade, https://www.fiercepharma.com/pharma/merck-confident-post-keytruda-future-70b-opportunity-next-decade-growth-drivers
9. 2026 - Notice of Annual Meeting & Proxy Statement - Merck.com, https://www.merck.com/wp-content/uploads/sites/124/2026/04/2026-Merck-Proxy-Statement.pdf
10. Fourth-Quarter 2025 Sales and Earnings - Merck.com, https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Earnings-Presentation.pdf
11. Merck & Co., Inc, Rahway, NJ USA First-Quarter 2026 Sales and Earnings Prepared Remarks, https://www.merck.com/wp-content/uploads/sites/124/2026/04/1Q26-Merck-Prepared-Remarks.pdf
12. Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China - AP News, https://apnews.com/article/merck-sales-forecast-gardasil-china-d95287118545d8620ebc8034cecd0d1e
13. First-Quarter 2026 Sales and Earnings - Merck.com, https://www.merck.com/wp-content/uploads/sites/124/2026/04/1Q26-Merck-Earnings-Presentation.pdf
14. Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline - MSD, https://www.msd.com/news/merck-co-inc-rahway-n-j-usa-announces-fourth-quarter-and-full-year-2025-financial-results-highlights-progress-advancing-broad-diverse-pipeline/
15. EDITED TRANSCRIPT - MRK.N - Q1 2026 Merck & Co Inc Earnings Call EVENT DATE/TIME, https://www.merck.com/wp-content/uploads/sites/124/2026/05/MRK-USQ_Transcript_2026-04-30.pdf
16. Merck stakes $9.2B on Cidara and its long-acting flu drug | BioPharma Dive, https://www.biopharmadive.com/news/merck-cidara-acquire-flu-antiviral-drug/805513/
17. What Prompted Vivo Capital's Exit from Cidara Therapeutics - Kavout, https://www.kavout.com/market-lens/what-prompted-vivo-capital-s-exit-from-cidara-therapeutics
18. Merck to Complete Acquisition of Cidara Therapeutics, https://www.merck.com/news/merck-to-complete-acquisition-of-cidara-therapeutics/
19. Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML), https://ir.ternspharma.com/news-releases/news-release-details/merck-acquire-terns-pharmaceuticals-inc-expanding-its-hematology/
20. Merck Completes Acquisition of Terns Pharmaceuticals, Inc., https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/
21. Merck flies toward CML asset in $6.7B Terns acquisition - Fierce Biotech, https://www.fiercebiotech.com/biotech/merck-flies-toward-promising-cml-asset-67b-terns-acquisition
22. Summit's PD-1/VEGF to take center stage at ASCO, with wide impact for peers - BioSpace, https://www.biospace.com/drug-development/summits-pd-1-vegf-to-take-center-stage-at-asco-with-wide-impact-for-peers
23. Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? | PharmaVoice, https://www.pharmavoice.com/news/pharma-merck-summit-vegf-pd1-drug-research-cancer/821919/
24. WCLC25: Summit's Keytruda challenger faces more questions over regional data differences | FirstWord Pharma, https://firstwordpharma.com/story/5995374
25. United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy, https://www.businesswire.com/news/home/20260302493703/en/United-Therapeutics-Corporation-Announces-Ralinepag-Achieved-55-Reduction-in-Risk-of-Clinical-Worsening-in-Pivotal-Pulmonary-Arterial-Hypertension-Study-Delivering-Exceptional-Highly-Statistically-Significant-Efficacy
26. United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac condition, https://www.fiercebiotech.com/biotech/united-therapeutics-phase-3-win-tees-filing-challenge-jj-cardiac-condition
27. Earnings call transcript: Merck's Q1 2026 earnings beat forecasts but stock dips By Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-mercks-q1-2026-earnings-beat-forecasts-but-stock-dips-93CH-4650200
28. Merck still sees 'compelling' outlook for Terns leukemia drug | BioPharma Dive, https://www.biopharmadive.com/news/merck-terns-leukemia-drug-deal-data-q1-2026-earnings/818949/
29. Merck & Co., Inc. Revenue (MRK) - MLQ.ai, https://mlq.ai/companies/merck-co-inc/revenue/
30. Merck & Company, Inc. (MRK): Investor Outlook With A 2.62% Dividend Yield And Robust Buy Ratings - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/merck-company-inc-mrk-investor-outlook-with-a-2-62-dividend-yield-and-robust-buy-ratings/4121255489
31. This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026 - Barchart.com, https://www.barchart.com/story/news/3215326/this-blue-chip-dividend-stock-is-outperforming-the-s-p-500-in-2026
32. Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML), https://www.merck.com/bdl_item/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/
33. Merck Reports $16.3B Q1 Revenue Despite a $9B One-Time Cidara Charge | TIKR.com, https://www.tikr.com/blog/merck-reports-16-3b-q1-revenue-despite-a-9b-one-time-cidara-charge
34. Merck Temporarily Halts Gardasil Shipments to China - Pharmaceutical Commerce, https://www.pharmaceuticalcommerce.com/view/merck-temporarily-halts-gardasil-shipments-to-china
35. Big pharma faces headwinds in China as vaccine sales decline, https://www.pharmaceutical-technology.com/features/big-pharma-faces-headwinds-in-china-as-vaccine-sales-decline/
36. With Gardasil demand shortfall in China, Merck and Zhifei adjust their partnership - Fierce Pharma, https://www.fiercepharma.com/pharma/gardasil-demand-shortfall-merck-and-china-partner-zhifei-adjust-their-partnership
37. MRK - Merck stock dividend history, payout ratio & dates - FullRatio, https://fullratio.com/stocks/nyse-mrk/dividend
38. Merck (NYSE: MRK) 2026 proxy links pay, R&D and $70B pipeline, https://www.stocktitan.net/sec-filings/MRK/def-14a-merck-co-inc-definitive-proxy-statement-b6507f172779.html
39. MRK-12.31.2025-10K-FINAL.pdf - Merck.com, https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf
40. Merck&Co Stock Dividend History & MRK Dividend Yield - Investing.com, https://www.investing.com/equities/merck---co-dividends
41. MRK Merck & Co., Inc. Historical Stock Price & Data - Seeking Alpha, https://seekingalpha.com/symbol/MRK/historical-price-quotes
42. Merck CEO granted new stock options and RSUs | MRK Insider Trading, https://www.stocktitan.net/sec-filings/MRK/form-4-merck-co-inc-insider-trading-activity-00d7e2fb2b5b.html
43. Merck & Co., Inc. (MRK) - rentseek.ing, https://rentseek.ing/t/MRK
44. MRK Technical Analysis for Merck & Company Stock - Barchart.com, https://www.barchart.com/stocks/quotes/MRK/technical-analysis
45. Merck & Co (MRK) - Technical Analysis - US 30 - Investtech, https://www.investtech.com/main/market.php?CompanyID=10100028
46. Merck (MRK) Stock: Analysts Raise Price Target, Outperfo... - FMP, https://site.financialmodelingprep.com/market-news/merck-mrk-stock-analysts-raise-price-target-outperform
47. Merck (MRK) Stock Sinks As Market Gains: Here's Why - July 10, 2026 - Zacks.com, https://www.zacks.com/stock/news/2951960/merck-mrk-stock-sinks-as-market-gains-heres-why